Our competences as a preclinical oncology CRO build on more than two decades of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet. We have extensive experience in design and execution of preclinical studies for drug development within oncology and immuno-oncology. We can perform studies with cell line based models as well as PDX models available through the START-MINERVA collaboration. Studies can be designed to take advantage of our capabilities of orthotopic and metastatic models, external radiation therapy, and advanced non-invasive imaging.

Interested to learn more about our preclinical oncology CRO services? Contact us to discuss how we can accelerate your drug development program.

Our capabilities

Subcutaneous xenograft models (rats and mice)

Targeted radionuclide therapy

Orthotopic xenograft models

PET/CT imaging

Subcutaneous and orthotopic syngeneic models

SPECT/CT imaging

PDX models, including orthotopic implantation

MR imaging

External radiation therapy

Optical (bioluminescence) imaging

Contact Person

Carsten H. Nielsen, PhD

Co-founder, CEO